ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / MGX / earnings
ALGS (22) ESLA (39) GNTA (50) EVAX (48) ⌘ Pro Terminal →

Metagenomi Therapeutics Inc. (MGX) Next Earnings Date & Expected ±12.5% Move

$0.78 -6.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.77

Metagenomi Therapeutics Inc. (MGX) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $31.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Metagenomi Therapeutics Inc. (NASDAQ: MGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $0.78 (-6.01% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGX ranks #957 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MGX compare to ALGS and ESLA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGX carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, MGX leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MGX?
▼

Per MGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785279), Metagenomi Therapeutics Inc. generated $25.2M in revenue (-51.8% YoY), -$87.9M in net income, and -$89.5M in free cash flow against $221.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.77 (-1.27%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510024
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (4)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.4% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE MGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (24/100 Composite)
🔍 WHY MGX SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 39.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$1.02-20.6% Next Q
Q2 (-2Q)
29
Grade E$0.81-4.9% Next Q
Q3 (-1Q)
27
Grade E$0.77+1.3% Next Q
Current
24
Grade E$0.78-10.9% Hist 90D α
Trajectory: E (32) → E (24)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MGX currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.82) forces dealer call-delta covering toward $2.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 24%NO 76%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing
$1.00 (-12.5%)Spot $0.78$0.88 (+12.5%)
MODEL EARNINGS SETUP GAUGE

MGX Quantitative Pre-Earnings Setup: 24/100

Trailing EPS: $4.25 • YoY Revenue Growth: -51.8%

Model Bullish Setup (24/100)Model Risk Weight (76/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$25.2M-$87.9M-$89.5M52%
FY 20242024-12-31$52.3M-$78.1M-$112.2M52%
FY 20232023-12-31$44.8M-$68.3M-$91.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MGX)

  • ✓Walkthrough of MGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.68%▼ DESCENDING CHANNEL
2026-11-02O $0.82H $0.83L $0.78C $0.78VOL 72.0K
RES: $1.09SUP: $0.69SMA50: $1.04SMA200: $1.29
$1.94$1.62$1.29$0.97$0.65RES $1.09SUP $0.69$0.782026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MGX Butterfly Map → + Track MGX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MGX)

Health Care Rank #957 of 1016 ⚔️ ALGS vs MGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MGX vs. ALGS, ESLA, GNTA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Metagenomi Therapeutics Inc. (MGX) ranks #957 by composite RQD confidence (24/100, grade E) and #801 by equity capitalization ($31.4M). Within this direct 5-issuer industry benchmark cohort, MGX leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with MGX at 24/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MGX ACTIVE
Metagenomi Therapeutics Inc.
E 24/100 — — -35.0% -6.01% $31.4M Benchmark Subject
ALGS
Aligos Therapeutics Inc.
E 22/100 — — -35.0% -4.57% $31.4M /algs-vs-mgx →
ESLA
Estrella Immunopharma Inc.
D- 39/100 — — -35.0% -12.27% $31.7M /esla-vs-mgx →
GNTA
Genenta Science S.p.A.
D 50/100 — — — -0.27% $29.9M /gnta-vs-mgx →
EVAX
Evaxion A/S
D 48/100 — — — -4.87% $27.8M /evax-vs-mgx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001785279

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Metagenomi Therapeutics Inc. (MGX) reported GAAP revenue of $25.2M (-51.8% vs. FY2024 revenue of $52.3M , and -43.7% cumulative change since FY2023) , GAAP net income of -$87.9M, operating cash flow of -$88.9M, and free cash flow of -$89.5M (+20.3% YoY). On the balance sheet, MGX closed FY2025 with $221.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $25.2M -$87.9M -$88.9M -$89.5M $221.1M —
FY2024 (FY) 2024-12-31 $52.3M -$78.1M -$109.1M -$112.2M $324.6M —
FY2023 (FY) 2023-12-31 $44.8M -$68.3M -$91.4M -$91.4M — —

3. MGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Metagenomi Therapeutics Inc. (NASDAQ: MGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $0.78 (-6.01% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGX ranks #957 in composite RQD confidence.

How does MGX compare to ALGS and ESLA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGX carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, MGX leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MGX?

Per MGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785279), Metagenomi Therapeutics Inc. generated $25.2M in revenue (-51.8% YoY), -$87.9M in net income, and -$89.5M in free cash flow against $221.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MGX trading relative to its 50-day, 200-day, and 52-week technical levels?

MGX last traded at $0.78 (-6.01% on volume of 77,878 shares), positioning the stock -25.00% below its 50-day simple moving average ($1.04) and -39.53% below its 200-day simple moving average ($1.29). Across its 52-week range of $0.75 to $2.62, MGX sits at the 1.6% percentile with a 14-day RSI of 39.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.88).

MGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is MGX's next earnings date?

Based on SEC filing cadence, Metagenomi Therapeutics Inc. (MGX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MGX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for MGX, spanning a range between $1 and $0.88.

Direct Sub-Reports: MGX RQD Cockpit MGX 12M Forecast MGX Earnings & Move MGX Dividends & DRIP MGX Insiders & 13F MGX Whale Options MGX Profit Sankey MGX News & Why
ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MGX — Metagenomi Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Metagenomi Therapeutics Inc. (MGX) carries a composite score of 24/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $0.78 (-6.01%). Fundamental cash generation scores 5/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 4/20, insider conviction scores 3/20, macro regime alignment scores 7/20 (Beta 1.00), and forensic balance-sheet protection scores 5/20 (Altman Z-Score 0.20, Piotroski F-Score 1/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Biological Products (No Diagnostic Substances), upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $0.75 – $2.62.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), MGX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

MGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Metagenomi Therapeutics Inc. (MGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MGX Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance • 200d ago
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative geneti

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MGX Bull vs. Bear Conversation Board — What's Your Call at $0.78?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MGX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on MGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.73 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MGX (E • RQD 24/100) a Buy at $0.83?

Welcome to the MGX (Metagenomi Therapeutics Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.68 (-18.1%)
Spot @ $0.83

Pump the brakes on MGX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Metagenomi Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.05 (+26.5%)
Spot @ $0.83

MGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MGX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.83 (52-wk range $0.75 - $2.62), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%